TY - JOUR
T1 - Structure-based design of a B cell antigen from B. pseudomallei
AU - Gaudesi, Davide
AU - Peri, Claudio
AU - Quilici, Giacomo
AU - Gori, Alessandro
AU - Ferrer-Navarro, Mario
AU - Conchillo-Solé, Oscar
AU - Thomas, Rachael
AU - Nithichanon, Arnone
AU - Lertmemongkolchai, Ganjana
AU - Titball, Richard
AU - Daura, Xavier
AU - Colombo, Giorgio
AU - Musco, Giovanna
PY - 2015/3/20
Y1 - 2015/3/20
N2 - © 2014 American Chemical Society. Burkholderia pseudomallei is the etiological agent of melioidosis, a severe endemic disease in South-East Asia, causing septicemia and organ failure with high mortality rates. Current treatments and diagnostic approaches are largely ineffective. The development of new diagnostic tools and vaccines toward effective therapeutic opportunities against B. pseudomallei is therefore an urgent priority. In the framework of a multidisciplinary project tackling melioidosis through reverse and structural vaccinology, BPSL1050 was identified as a candidate for immunodiagnostic and vaccine development based on its reactivity against the sera of melioidosis patients. We determined its NMR solution structure and dynamics, and by novel computational methods we predicted immunogenic epitopes that once synthesized were able to elicit the production of antibodies inducing the agglutination of the bacterium and recognizing both BPSL1050 and B. pseudomallei crude extracts. Overall, these results hold promise for novel chemical biology approaches in the discovery of new diagnostic and prophylactic tools against melioidosis.
AB - © 2014 American Chemical Society. Burkholderia pseudomallei is the etiological agent of melioidosis, a severe endemic disease in South-East Asia, causing septicemia and organ failure with high mortality rates. Current treatments and diagnostic approaches are largely ineffective. The development of new diagnostic tools and vaccines toward effective therapeutic opportunities against B. pseudomallei is therefore an urgent priority. In the framework of a multidisciplinary project tackling melioidosis through reverse and structural vaccinology, BPSL1050 was identified as a candidate for immunodiagnostic and vaccine development based on its reactivity against the sera of melioidosis patients. We determined its NMR solution structure and dynamics, and by novel computational methods we predicted immunogenic epitopes that once synthesized were able to elicit the production of antibodies inducing the agglutination of the bacterium and recognizing both BPSL1050 and B. pseudomallei crude extracts. Overall, these results hold promise for novel chemical biology approaches in the discovery of new diagnostic and prophylactic tools against melioidosis.
U2 - 10.1021/cb500831y
DO - 10.1021/cb500831y
M3 - Article
SN - 1554-8929
VL - 10
SP - 803
EP - 812
JO - ACS Chemical Biology
JF - ACS Chemical Biology
IS - 3
ER -